Armed with an asset that could be an improvement on Pfizer’s (NYSE: PFE) blockbuster smoking cessation drug Chantix/Champix (varenicline), Achieve Life Sciences (Nasdaq: ACHV) has confidence in its prospects of addressing the global smoking health and nicotine addiction epidemic.
This asset is cytisinicline, an alkaloid that occurs naturally in several plant genera and is a nicotine-receptor partial agonist, and it could serve not just a market of smokers that numbers 29 million in the USA alone, but also the growing population of e-cigarette users, or vapers, which currently totals 11 million Americans.
With a New Drug Application (NDA) set to be filed for smoking cessation imminently, Achieve’s chief executive Richard Stewart is confident that the company has the first new nicotine dependence treatment in nearly 20 years on its hands.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze